Commentary Open Access
Volume 2 | Issue 2 | DOI: https://doi.org/10.33696/cancerbiology.2.026

SorLA Targeting - A Method to Overcome Therapy Resistance in Breast Cancer

  • 1Turku Bioscience Centre and FICAN West Cancer Center, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland
  • 2Department of Life Technologies, University of Turku, FI-20520 Turku, Finland
  • #Boehringer Ingelheim RCV GmbH & Co KG, A-1121 Vienna, Austria
+ Affiliations - Affiliations

Corresponding Author

Hussein Al-Akhrass, hussein.al-akhrass@boehringer-ingelheim.com

Received Date: November 02, 2021

Accepted Date: December 02, 2021


In breast cancer, tyrosine kinase-type cell surface receptor HER2-targeted therapies do not achieve a sustained inhibition of oncogenic signaling. Therapy-resistant tumors compensate for HER2 inhibition through several mechanisms, including increased expression of other cell-surface receptors most notably HER3. HER3 remains currently undruggable despite extensive clinical efforts. Durable efficacy of HER2-based therapy regimens requires, therefore, effective inhibition of HER2 and HER3. Our recent work has unraveled a previously unappreciated role of HER2 and HER3 intracellular trafficking in promoting drug resistance in breast cancer. Sortilinrelated receptor (SorLA) is a sorting receptor mainly investigated with regard to neuronal and metabolic diseases. We discovered oncogenic properties of SorLA through supporting HER2 and HER3 expression and signaling, thus mediating cancer response to growth factors to promote HER2-therapy resistance. Here we briefly review the mechanisms of SorLA supported oncogenic signaling in breast cancer and discuss their translational and clinical potential.

Author Information X